Skip to content
Do you have adblock enabled?
 
If you can read this, either the style sheet didn't load or you have an older browser that doesn't support style sheets. Try clearing your browser cache and refreshing the page.

(NPR)   A new Alzheimer's drug didn't cause bleeding brains in 4/5 patients   (npr.org) divider line
    More: Interesting, Alzheimer's disease, Clinical trial, experimental drug, Dr. Madhav Thambisetty of the National Institute, infusions of lecanemab, Dr. Christopher van Dyck, Cognition, rate of cognitive decline  
•       •       •

393 clicks; posted to STEM » on 30 Nov 2022 at 3:30 PM (9 weeks ago)   |   Favorite    |   share:  Share on Twitter share via Email Share on Facebook



10 Comments     (+0 »)
View Voting Results: Smartest and Funniest
 
2022-11-30 3:49:16 PM  
Sounds like you have to administer the drug before there's any signs of Alzheimer's. Is this the new statin?
 
2022-11-30 4:08:20 PM  
People who got infusions of lecanemab scored about half a point better on a zero-to-18-point scale of mental functioning, a slight but statistically significant difference.

Question is, how far behind normal people are Alzheimer patients (or at least, Alzheimer patients at this stage of the disease) on this scale? If it's 1 or 2 points, then maybe that's a pretty big deal; if it's 10 points, it seems like it's not worth the risk.
 
2022-11-30 4:24:26 PM  

Arkanaut: People who got infusions of lecanemab scored about half a point better on a zero-to-18-point scale of mental functioning, a slight but statistically significant difference.

Question is, how far behind normal people are Alzheimer patients (or at least, Alzheimer patients at this stage of the disease) on this scale? If it's 1 or 2 points, then maybe that's a pretty big deal; if it's 10 points, it seems like it's not worth the risk.


I think the NYTimes article said it slowed the progression by 27%.
 
2022-11-30 4:47:36 PM  
Don't worry about that 5th patient, he was an asshole anyway.
 
2022-11-30 4:51:57 PM  

LurkerSupreme: Don't worry about that 5th patient, he was an asshole anyway.


Was he the dentist who didn't recommend Trident?
 
2022-11-30 5:35:01 PM  

Arkanaut: LurkerSupreme: Don't worry about that 5th patient, he was an asshole anyway.

Was he the dentist who didn't recommend Trident?


Yes, and also the one person who refused to save money on their car insurance by switching to Geico.
 
2022-11-30 9:08:13 PM  
"I'm a person living with a progressive and fatal disease," says Michael Zuendel, 68, who has been taking Aduhelm since he was diagnosed with mild cognitive impairment, an early stage of Alzheimer's. "I do not have time to wait for the perfect research study."

Sucks to be you who can afford the 50K+ per year for for Aduhelm. Unfortunately science is not based on your wallet or your feelings. If a drug causes adverse events in 20% of the people who receive it it is not good enough. I am sorry you do not understand how clinical trials work.
 
2022-11-30 9:33:06 PM  
Dave Brubeck - Take Five
Youtube tT9Eh8wNMkw
 
2022-11-30 10:41:36 PM  

LockeOak: Arkanaut: People who got infusions of lecanemab scored about half a point better on a zero-to-18-point scale of mental functioning, a slight but statistically significant difference.

Question is, how far behind normal people are Alzheimer patients (or at least, Alzheimer patients at this stage of the disease) on this scale? If it's 1 or 2 points, then maybe that's a pretty big deal; if it's 10 points, it seems like it's not worth the risk.

I think the NYTimes article said it slowed the progression by 27%.


37%, which given what I've seen about lecanemab prior to today's claim that 37% seems incredibly misleading.
 
2022-12-01 7:19:24 PM  
 
Displayed 10 of 10 comments

View Voting Results: Smartest and Funniest

This thread is closed to new comments.

Continue Farking




On Twitter


  1. Links are submitted by members of the Fark community.

  2. When community members submit a link, they also write a custom headline for the story.

  3. Other Farkers comment on the links. This is the number of comments. Click here to read them.

  4. Click here to submit a link.